RT Journal Article
SR Electronic
T1 Combined association of obesity and other cardiometabolic diseases with severe COVID-19 outcomes: a nationwide cross-sectional study of 21,773 Brazilian adult and elderly inpatients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.14.21257204
DO 10.1101/2021.05.14.21257204
A1 Silva, Natanael J
A1 Ribeiro-Silva, Rita C
A1 Ferreira, Andrêa JF
A1 Teixeira, Camila SS
A1 Rocha, Aline S
A1 Alves, Flávia Jôse O
A1 Falcão, Ila R
A1 Pinto, Elizabete J
A1 Antônio ST Santos, Carlos
A1 Fiaccone, Rosemeire L
A1 Ichihara, Maria Yury T
A1 Paixão, Enny S
A1 Barreto, Mauricio L
YR 2021
UL http://medrxiv.org/content/early/2021/05/18/2021.05.14.21257204.abstract
AB Objectives To investigate the combined association of obesity, diabetes mellitus (DM), and cardiovascular disease (CVD) with severe COVID-19 outcomes in adult and elderly inpatients.Design Cross-sectional study based on registry data from Brazil’s influenza surveillance system.Setting Public and private hospitals across Brazil.Participants Eligible population included 21,942 inpatients aged ≥20 years with positive RT-PCR test for SARS-CoV-2 until Jun 9th, 2020.Main outcome measures Severe COVID-19 outcomes were non-invasive and invasive mechanical ventilation use, ICU admission, and death. Multivariate analyses were conducted separately for adults (20-59 years) and elders (≥60 years) to test the combined association of obesity (without and with DM and/or CVD) and degrees of obesity with each outcome.Results A sample of 8,848 adults and 12,925 elders were included. Among adults, obesity with DM and/or CVD showed higher prevalence of invasive (PR 3.76, 95%CI 2.82-5.01) and non-invasive mechanical ventilation use (2.06, 1.58-2.69), ICU admission (1.60, 1.40-1.83), and death (1.79, 1.45-2.21) compared with the group without obesity, DM, and CVD. In elders, obesity alone (without DM and CVD) had the highest prevalence of ICU admission (1.40, 1.07-1.82) and death (1.67, 1.00-2.80). In both age groups, obesity alone and combined with DM and/or CVD showed higher prevalence in all outcomes than DM and/or CVD. A dose-response association was observed between obesity and death in adults: class I 1.32 (1.05-1.66), class II 1.41 (1.06-1.87), and class III 1.77 (1.35-2.33).Conclusions The combined association of obesity, diabetes, and/or CVD with severe COVID-19 outcomes may be stronger in adults than in elders. Obesity alone and combined with DM and/or CVD had more impact on the risk of COVID-19 severity than DM and/or CVD in both age groups. The study also supports an independent relationship of obesity with severe outcomes, including a dose-response association between degrees of obesity and death in adults.Article summary Strengths and limitations of this study: This is the first study that describes the independent and combined relationship of obesity with COVID-19 severity in Brazil, one of the biggest epicenters of the pandemic worldwide.The study was based on registry data of a large nationwide sample of patients admitted, due to severe SARS-CoV-2 infection, to public and private hospitals across the country.The large sample size and data availability allowed us to analyze the combined association of obesity, diabetes and cardiovascular disease with severe COVID-19 outcomes, separately by age groups and controlled by important confounding variables, e.g. underlying comorbidities.The cross-sectional study design does not allow causal inference, and generalization of results must be cautious since only hospitalized cases of severe COVID-19 were included.As the study used routinely collected data, which has not been designed primarily for research purposes, it may bring well-known limitations related to missing, underestimation, and potential misclassification.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAll authors are affiliated to the Centre for Data and Knowledge Integration for Health (CIDACS) that is funded and supported by MCTI/ CNPq/ MS/ SCTIE/ Decit/ Bill & Melinda Gates Foundation's GCE Brazil (OPP1142172), Wellcome Trust (202912/Z/16/Z), the Brazilian Health Surveillance Secretariat, Ministry of Health, Bahia State, Research Support Foundation of the State of Bahia (FAPESB), the Research and Project Funding Agency (FINEP), and the Secretariat of Science and Technology of the State of Bahia (SECTI). Dr Paixao is a fellow supported by the Wellcome Trust (213589/Z/18/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:As the study exclusively used publicly available de-identified data, ethics approval by a research ethics committee and informed consent are waived per Resolution n. 466/2012 of the National Health Council of Brazil’s Commission of Ethics in Research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is freely available without restriction at https://opendatasus.saude.gov.br/dataset/bd-srag-2020. Code book and analytic code will be made available upon request from the corresponding author. https://opendatasus.saude.gov.br/dataset/bd-srag-2020